<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688881</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02-052</org_study_id>
    <nct_id>NCT02688881</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors</brief_title>
  <official_title>Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm, pilot study of sirolimus in patient with
      Phosphatidylinositide-3-kinase (PIK3CA) mutation, PIK3CA amplification , PIK3CA-AKT pathway
      aberration Refractory solid tumor and/or specific sensitivity to mTOR inhibitors by Avatar
      scan that has progressed following standard therapy or that has not responded to standard
      therapy or for which there is no standard therapy.

      sirolimus 1mg will be administered orally daily. To investigate the efficacy and safety of
      sirolimus in patient with Refractory solid tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>6 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of safety</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sirolimus 1mg will be administered orally daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Rapamune</description>
    <arm_group_label>sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of fully informed consent prior to study specific procedures.

          -  Patients must be &gt;= 19 years of age

          -  Phosphatidylinositide-3-kinase (PIK3CA) mutation, PIK3CA amplification , PIK3CA-AKT
             pathway aberration( H1047R, E542K, E545K, PTEN LOSS) Refractory solid tumor and/or
             specific sensitivity to mTOR inhibitors by Avatar scan that has progressed following
             standard therapy or that has not responded to standard therapy or for which there is
             no standard therapy.

          -  ECOG Performance status0-2

          -  Have measurable or evaluated disease based on RECIST 1.1 as determined by
             investigator.

          -  Adequate Organ Function Laboratory values

               -  Absolute neutrophil count &gt;= 1.5 x 109/L, Hemoglobin &gt;= 9g/dL, Platelets&gt;=75 x
                  109/L Bilirubin &lt;= 1.5 x upper limit of normal AST/ALT &lt;= 2.5 X upper limit of
                  normal(5.0 x upper limit of normal, for subject with liver metastases)
                  Creatinine&lt;= 1.5 X UNL

          -  Patients of child-bearing potential should be using adequate contraceptive measures
             should not be breast feeding and must have a negative pregnancy test prior to start of
             dosing

          -  Adequate heart function

        Exclusion Criteria:

          -  Patients with second primary cancer, except:adequately treated non-melanoma skin
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumor
             curatively treated with no evidence of disease for &lt;= 5 years.

          -  Has known active central nervous system(CNS) metastases

          -  Has an active infection requiring systemic therapy

          -  Pregnancy or breast feeding

          -  Patients with cardiac problem

          -  Any previous treatment with sirolimus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeeyun Lee, MD,Ph.D.</last_name>
    <phone>2-3410-3459</phone>
    <phone_ext>82</phone_ext>
    <email>jyun.lee@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>99999</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeeyun Lee, MD</last_name>
      <phone>+82-10-9933-1779</phone>
      <email>jyun.lee@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Jeeyun Lee, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jeeyun Lee</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

